Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent
| Autor: | Linda D. Gillam, Denise E. Bruns, Eva Hausnerova, Douglas S. Segar, John S. Gottdiener, Jorge Cheirif, Jerald L Cohen |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
medicine.medical_specialty
Contrast enhancement business.industry media_common.quotation_subject Image enhancement Endocardial border Microsphere Safety profile Multicenter trial medicine Contrast (vision) Radiology Cardiology and Cardiovascular Medicine Nuclear medicine business Short duration media_common |
| Zdroj: | Journal of the American College of Cardiology. 32:746-752 |
| ISSN: | 0735-1097 |
| Popis: | Objectives. The echocardiographic contrast-enhancing effects and safety profile of ALBUNEX (a suspension of air-filled albumin microspheres) were compared with the new contrast agent OPTISON (formerly FS069: a suspension of albumin microspheres containing the gas perfluoropropane) in 203 patients with inadequate noncontrast echocardiograms. Background. The efficacy of ALBUNEX has been limited by its short duration of action. By using perfluoropropane instead of air within the microsphere, its duration of action is increased. Methods. Each patient received ALBUNEX (0.8 and 0.22 mL/kg) and OPTISON (0.2, 0.5, 3.0, and 5.0 mL) on separate days a minimum of 48 hours apart. Echocardiograms were evaluated for increase in left ventricular (LV) endocardial border length, degree of LV opacification, number of LV endocardial border segments visualized, conversion from a nondiagnostic to a diagnostic echocardiogram, and duration of contrast enhancement. A thorough safety evaluation was conducted. Results. Compared with ALBUNEX, OPTISON more significantly improved every measure of contrast enhancement. OPTISON increased well-visualized LV endocardial border length by 6.0 ± 5.1, 6.9 ± 5.4, 7.5 ± 4.7, and 7.6 ± 4.8 cm, respectively, for each of the four doses, compared with only 2.2 ± 4.5 and 3.4 ± 4.6 cm, respectively, for the two ALBUNEX doses (p Conclusion. OPTISON appears to be a safe, well-tolerated echocardiographic contrast agent that is superior to ALBUNEX. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|